Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA’s Novel Approvals Again Led By Oncology And Neurology, But Dermatology Also Shone In 2022

Jan 19 2023

• By Bridget Silverman

US FDA 2022 Novel Approvals — • Source: Shutterstock

Related Content

US FDA’s Use Of CRLs Hit A High Note In 2022: One-Third Of Novel Agent Decisions Were Not Approvals

Jan 10 2023

US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies

Jan 04 2023

With 37 Novel Approvals in 2022, US FDA CDER’s Five-Year Hot Streak Comes To An End; Gene Therapies Carry CBER To 8 Novel Approvals

Jan 02 2023

Fewer Drug Launches In 2022, But Standouts Among Them

Jan 03 2023

Related Companies

Provention Bio, Inc.

Eli Lilly and Company

Genentech, Inc.

Merck & Co., Inc.

Bristol Myers Squibb Company

AstraZeneca PLC

Immunocore, Ltd.

Ferring Pharmaceuticals

Johnson & Johnson

Taiho Pharmaceutical Co. Ltd.

Mirati Therapeutics, Inc.

Pfizer Inc.

Boehringer Ingelheim GmbH

Eisai Co., Ltd.

Biogen, Inc.

Alnylam Pharmaceuticals Inc.

Amylyx Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.

Levo Therapeutics, Inc.

Phathom Pharmaceuticals, Inc.

Moderna, Inc.

GSK plc

Gilead Sciences, Inc.

Scynexis, Inc.

Sanofi

Agios Pharmaceuticals, Inc.

CTI BioPharma Corp.

Additional Topics

United States Approvals Drug Approval Standards Drug Review Regulation Pink Sheet Perspectives BioPharmaceutical Cancer Neurology Dermatology

More from Pink Sheet Perspectives

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window